

### Daftar Pustaka

- Al-Jamei, S. A., Albsoula, A. Y., Bakri, F. G., Al-Bakri A. G. 2018. Extended spectrum  $\beta$ - lactamase producing E.coli in urinary tract infections : A two-center, cross sectional study of prevalence, genotypes and risk factors in Amman, Jordan. *J Infect Public Health*.
- Al-Yousef, S.A., Younis, S., Farrag, E., Mousa, H.Sh., Bayoumi, F.S. and Ali, A.M. 2016. Clinical and laboratory Profile of Urinary Tract Infections Assosited with Extended Spectrum  $\beta$ -Lactamase Producing Escherichia coli and Klebsiella pneumoniae. *Annals of Clinical and Laboratory Science*;46(4).
- Ben-Ami, R., Rodriguez-Bano, J., Arslan, H., Pitout, J.D.D., Quentin, C., Calbo, E.S., Azap, O.K., Arpin, C., Pascual, A., Livermore, D.M., Garau, J. and Carmeli, Y. 2009. A Multinational Survey of Risk Factors for Infection with Extended-Spectrum  $\beta$ -Lactamase-Producing Enterobacteriaceae in Nonhospitalized Patients. *CID* ; 49 : 682-690.
- Benton, B., Breukink, E., Visscher I., Debabov, D., Lunde, C., Janc, J., Mammen, M., Humprey, P. 2007. Telavancin inhibits peptidoglycan biosynthesis through preferential targeting of transglycosylation: evidence for a multivalent interaction between telavancin and lipid II. *Int. J. Antimicrob. Agents* 29, 51–52.
- Bird, J., Browning, R., Hobson, R.P., MacKenzie, F.M., Brand, J & Gould, I.M. 1998 Multiply-resistant Klebsiella pneumoniae: failure of spread in community-based elderly care facilities. *Journal of Hospital Infection*; 40 : 243-247.
- Bradford, P. A., Urban, C., Mariano, N., Projan, S.J., Rahal, J.J., and Bushi, K. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. *Antimicrob. Agents Chemother.* 41:563–569.

- Briongos-Figuero, L.S., Gomez-Traveso, T., Bachiller-Luque, P., Gonzales, M. DG., Nieto-Gomez, A., Martin-Palacios, T., Sagrado-Gonzalez, M., Lita-Duenas, A., Castrillon-Perez, L. 2012. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended spectrum beta-lactamase (ESBL) producing enterobacteria. *Int J Clin Pract* ; 66:891-896.**
- Bush, K., Jacoby, G. A. 2010. Update Functional Classification of  $\beta$ -Lactamases. *America Society for Microbiology, Antimicrob. Agents Chemother*; Vol. 54, No. 3, Mar 2010, p. 969-967.**
- Bush, K., Jacoby, G. A., Medeiros, A. A. 1995. A Functional Classification Scheme for  $\beta$ -Lactamases and Its Corellation with Molecular Structure. *American Society for Microbiology. Antimicrob. Agents Chemother*; Vol. 39, No. 6, June 1995, p. 1211-1233.**
- Calbo, E., Romani, V., Xercavins, M., Gomez1 L., Vidall, C. G., Quintana S., Vila, J and Garauet, J. 2006. Risk factors for community-onset urinary tract infections due to *Escherichia coli* harbouring extended-spectrum beta-lactamases. *J Antimicrob Chemother* ;57(4):780–3.**
- Castanheira, M., Mills, J. C., Costello, S. E., Jones, R. N., Sader, H. 2015. Ceftazidime-avibactam activity tested against *Enterobacteriaceae* isolates from U.S. hospitals (2011 to 2013) and characterization of blactamase-producing strains. *Antimicrob Agents Chemother*;59:3509–17.**
- Charlson, M. E., Pompei, P., Ales, K. L., McKenziei, C.R. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*;40(5):373–383.**
- Colodner, R., Rock, W., Chazan, B., Keller, N., Guy N., Sakran W. 2004. Risk factors for the development of extended-spectrum  $\beta$ - lactamase producing bacteria in non hospitalized patients. *Eur.J. Clin. Microbiol. Infect.Dis* ; 23(3), 163-167.**
- Das, N., Barthakur, A.K. 2012. Antibiotic coresistance among extended spectrum beta lactamase producing urinary isolates in tertiary medical center. *Chron Young Sci*; 3:53-6.**

- Denis, B., Lafaurie, M., Donay, J. L. Fontaine, J-P., Oksenhendler, E., Raffoux, E., Hennequin, C., Allez, M., Socie, G., Maziers, N., Porcher, R., Molina, J-M. 2015. Prevalence, risk factors and impact on clinical outcome of extended-spectrum beta-lactamase producing *Escherichia coli* bacteremia : a five-year study. *Int J Infect Dis* ; 39 : 1-6.
- Denisuik, A. J., Lagace´-Wiens, P.R.S., Pitout, J. D., Mulvey, M.R., Simner, P.J., Tailor, F., Karlowsky, J.A., Hoban, D.J., Adam, H.J. and Zhanel, G.G. 2013. Molecular epidemiology of extended-spectrum b-lactamase-, AmpC b-lactamase- and carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. *J Antimicrob Chemother* ; 68 Suppl 1: i57– i65.
- E, Mahesh., Ramesh, D., Indumathi, V.A., Khan, M.W., Kumar, P.S., Punith, K. 2010. Risk Factors for Community Acquired Urinary Tract Infection caused by ESBL-producing Bacteria. *JACM* ;11:271-6.
- Ena, J., Arjona, F., Martinez-Peinado, C., Lopez-Perezagua Mdel M., Amador C. 2006. Epidemiology of urinary tract infections caused by extended-spectrum betalactamase-producing *Escherichia coli*. *Urology* ;68:1169–74.
- European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. (<http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014>)
- Fatimah, S., Iyad, N., Muhammad, Shanaz, U., Subia, J., Muhammad N Khan, and Seema, I Khan., 2018. Incidence of multidrug resistance and extended-spectrum beta-lactamase expression in community-acquired urinary tract infection among different age groups of patients *Indian J Pharmacol*. 2018 Mar-Apr; 50(2): 69–74. doi: [10.4103/ijp.IJP\\_200\\_17](https://doi.org/10.4103/ijp.IJP_200_17)

- Gudiol, C., Calatayud, L., Garcia-Vidal, C., Lora-Tamayo, J., Císnal, M., Duarte, R., Arnan, M., Marin, M., Carratalà, J., Gudiol, F. 2010. Bacteraemia due to extended spectrum beta-lactamase-producing *Escherichia coli* (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. *J Antimicrob Chemother*; 65(2):333–41.
- Gupta, S., and Maheshwari, V. 2017. Prevalence of ESBLs among Enterobacteriaceae and their Antibiotic Resistance Pattern from Various Clinical Samples. *Int.J.Curr.Microbiol.App.Sci* ; 6(9): 2620-2628
- Harris, A. D., McGregor, J. C., Johnson, J. A., Strauss, S.M., Moore, A.C., Standford, H.C., Hebden, J.N., and Morris Jr, J.G. 2007. Risk Factors for Colonization with Extended-Spectrum  $\beta$ -Lactamase-Producing Bacteria and Intensive Care Unit Admission. *Emerg Infect Dis*; 45;846-52
- Hauser, A. R. 2013. *Antibiotic Basics for Clinicians: The ABCs of Choosing the Right Antibacterial Agent 2<sup>nd</sup> Edition*. Philadelphia: Lippincott Williams & Wilkins.
- Hawser, S.P., Bouchillon, S.K., Hoban, D.J., Badal, R.E., Hsueh, P.R., Paterson, D.L. 2009. Emergence of high-levels of extended-spectrum- $\beta$ -lactamase-producing gram-negative bacilli in the Asia-Pacific region: Data from the study for monitoring antimicrobial resistance trends (SMART) program 2007. *Antimicrob. Agents Chemother*; 53: 3280–3284.
- Ikeda, Y., Mamiya, T., Nishiyama, H., Koseki, T., Mouri, A., Nabeshima, T. 2012 Risk factors for extended-spectrum beta-lactamase-producing *Escherichia coli* infection in hospitalized patients. *Nagoya J Med Sci* ;74:105e14.
- Japan Nosocomial Infections Surveillance. Annual open report 2014 (all facilities). ([http://www.nih-janis-jp/\\_Open\\_Report\\_Eng\\_2014\\_clsi](http://www.nih-janis-jp/_Open_Report_Eng_2014_clsi) 2012).

- Jones, R. N., Biedenbach, D. J., Gales, A. C. 2003. Sustained activity and spectrum of selected extended-spectrum b-lactams (carbapenems and cefepime) against *Enterobacter* spp. and ESBL-producing *Klebsiella* spp.: report from the SENTRY antimicrobial surveillance program (USA,1997-2000). *Int J Antimicrob Agents*; 21:1–7.**
- Jones, R. N., Flonta, M., Gurler, N., Cepparulo, M., Mendes, RE., Castanheira, M. 2014, Resistance surveillance program report for selected European nations (2011) . *Diagnose Microbiol Infect Dis*; 78:429–36.**
- Kandeel, A.Y. 2014. Prevalence and risk factors of extended-spectrum B-lactamases producing *Enterobacteriaceae* in a general hospital in Saudi Arabia. *Journal of Microbiology and Infectious Diseases*; 4 (02).**
- Kirasitin, P., Apisantharnarak, A., Laesripa, C. 2008. Molecular characterization and epidemiology of extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. *Antimicrob Agents Chemother* ;52(8):2818-24.**
- Kuntaman, K., Santoso, S., Wahjono, H., Mertaniasih, N.M., Lestari, E.S., Farida, H., Hapsari, R., Firmanti, S.C., AS, N., Santosaningsih, D., Purwono, P.B., Kusumaningrum, D. 2011. The sensitivity pattern of ESBL's (Extended Spectrum Beta Lactamase) Producing bacteria against Six antibiotics that routinely used in Clinical Setting. *Journal of the Indonesian Medical Association* ;61 (12) : 482-6.**
- Kuster, S.P., Hasse, B., Huebner, V., Bansal, V., Zbinden, R., Ruef, C., Ledergerber, B., Weber, R. 2010. Risk Factor for Infections Extended Beta-lactamase Producing *Escherichia coli* and *Klebsiella pneumoniae* at a Tertiary Care University Hospital in Switzerland. *Infection*; 38(1):33-40.**

- Leach, K. L., Swaney, S. M., Colca, J. R., McDonald, W.G., Blinn, J.R., Thomasco, L.M., Gadwood, R.C., Shinabarger, D., Xiong, L., Mankin, A.S. 2005. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. *Mol. Cell* ; 26: 393-402.
- Lee, H., Han, S. B., Kim, J. H., Kang, S., Durey, A. 2018. Risk factors of urinary tract infection caused by extended spectrum  $\beta$ -lactamase producing *Escherichia coli* in emergency department. *American J Emergency Medicine*.
- Mayers, D.L., Lerner, S.A., Ouellette, M., Sobel, J. D. 2009. *Antimicrobial Drug Resistance Volume 1 : Mechanisms of Drug Resistance*. New York : Humana Press.
- Mayers, D.L., Lerner, S.A., Ouellette, M., Sobel, J. D. 2009. *Antimicrobial Drug Resistance Volume 2 : Clinical and Epidemiological Aspects*. New York : Humana Press.
- Mendes, R. E., Mendoza, M., Singh, B., Castanheira, M., Bell, J.M., Turnidge, J.D., Lin, S.S.F., Jones, R.N. 2011 Regional resistance surveillance program results for 12 Asia-Pacific nations. *Antimicrob Agents Chemother*; 57:5721–6.
- Nakai, H., Hagihara, M., Kato, H., Hirai, T., Nishigama, N., Koizumi, Y., Sakanishi, D., Suematsu, H., Yamagishi, Y. 2016. Prevalence and risk factors of infections caused by extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Enterobacteriaceae*. *J.Infect Chemother*; 22; 319-326.
- Osthoff, M., McGuinness, S. L., Wagen, A. Z., Eisen, D. P. 2015. Urinary tract infections due to extended-spectrum beta lactamase producing Gram negative bacteria : identification of risk factors and outcome predictors in an Australian tertiary referral hospital. *Int J Infect Dis*;34:79–83.
- Paterson, D. L., Bonomo, R. A. 2005. Extended-spectrum  $\beta$ -lactamases: a clinical update. *Clin Microbiol Rev*; 18:657–86.

- Pitout, J.D.D., Nordmann P., Laupland, K. B., and Poirel, L. 2005. Emergence of Enterobacteriaceae producing extended-spectrum  $\beta$ -lactamases (ESBLs) in the community. *J. Antimicrobe. Chemother*; 56(1), 52-59.
- Razazi, V. K., Derde, L.P.G., Verachten, M., Legrand, P., Lesprit, P., Brun-Buisson, C. 2012 Clinical impact and risk factors for colonization with extended-spectrum  $\beta$ -lactamase producing bacteria in the intensive care unit. *Intensive Care Med*; 38:1769–1778
- Sanchez, G.V., Babiker, A., Master, R. N., Luu, T., Mathur, A., Bordon, J. 2017, Antibiotic resistance among urinary isolates from female outpatients *Journal of Travel Medicine*, Vol. 24, Suppl 1 S49 in the United States in 2003 and 2012. *Antimicrob Agents Chemother*; 60:2680–3.
- Silvia, N., Oliveira, M., Bandeira, A.C., Brites, C. 2006. Risk Factors Infection by Extended-Spectrum Beta-Lactamase Producing *Klebsiella pneumoniae* in a Tertiary Hospital In Salvador, Brazil. *Braz J Infect Dis. Jun*;10(3):191-3
- Smith, P.W., Seip, C.W., Schaefer, S.C., Bell-Dixon, C. 2000. Microbiologic survey of long-term care facilities. *Am J Infect Control*;28:8–13.
- Sobel, J.D., Kaye, D. 2014. Urinary tract infections. In: Mandell GL, Bennett JE, eds. *Principles and Practice of Infectious Diseases*, 8th ed. Philadelphia: Elsevier Saunders, 886-913.
- Strohl, W.R. 1997. *Biotech Antibiotics*. Marcel Dekker Inc., New York, USA.
- Straus, S.K., Hancock, R.E.W. 2006. Mode of action of the new antibiotic for gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptide. *Biochim. Biophys. Acta* 1758, 1215–1223.
- Swhwaber, M.J., Carmeli, Y. 2007. Mortality and delay in effective therapy associated with extended spectrum  $\beta$ -lactamase production in Enterobacteriaceae bacteremia; a systemic and metaanalysis. *J Antimicrob Chemother*; 60(5);913-920.

- To, K. K. W., Lo, W.U., Chan, J. F., Tse, H., Cheng, V.C.C., Ho, P.K. 2012. Clinical outcome of extended beta lactamase producing *Escherichia coli* bacteremia in an area with high endemicity. *Int J Infect Disease*17; e120-e124.
- Topaloglu, R., Er, I., Dogan, B. G., Bilginer, Y., Ozatin, F., Besbas, N., Ozcu, S., Bakkaloglu, A., Gur, D. 2010. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. *Pediatri Nephrol*; 25:919-25.
- Versalovic, J., Carroll, K. C., Funke, G., Jorgensen, J. H., Landry, M.L., Warnock, D.W. Eds. *Manual of Clinical Microbiology*. 10th ed. American Society of Microbiology 2011.
- Walker, S., McGeer, A., Simor, A.E., Evans- Amstrong, and Loeb, M. 2000. Why are antibiotics prescribed for asymptomatic bacteriuria in institutionalized elderly people?: A qualitative study of physicians' and nurses' perception. *CMAJ*. August 8; 163(3): 273-277.
- Wiener, J., J. P. Quinn, P. A. Bradford, R. V. Goering, C. Nathan, K. Bush, and R. A. Weinstein. 1999. Multiple antibiotic-resistant *Klebsiella* and *Escherichia coli* in nursing homes. *JAMA*; 281:517–523.
- Wroblewska, M.M., Rudnicka, J., Marchel, H., Luczak, M. 2006. Multidrug-resistant bacteria isolated from patients hospitalised in Intensive Care Units. *International Journal of Antimicrobial Agents*; 27(4) : 285–289.
- Yilmaz, E., Akalin, H., Ozbey, S., Kordan, Y., Sinirtas, M., Gurcuoglu, E., Ozakin, C., Heper, Y., Mistik, R., Helvacı, S. 2008. Risk factors in community acquired/onset urinary tract infections due to extended-spectrum beta-lactamases producing *Escherichia coli* and *Klebsiella pneumoniae*. *J Chemother* ; 20:581-5.